INSMED INCORPORATED (INSM): what the price requires

At today's price, INSMED INCORPORATED (INSM) is priced for today's economics sustained for ~17.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/INSM

Headline

FieldValue
TickerINSM
CompanyINSMED INCORPORATED
Current price$109.21/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid35.5x
Steady-state operating margin assumed32.9%
Must persist for17.5y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 10% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.6 years.

How unusual the bet is: elevated

ReferenceValue
vs own history-0.43σ
sustained it ~10 years at this level14%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset—0—
Earnings—0—
Relative7.18x2expensive
Growth3.21x1expensive

Families that call it expensive: Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=3)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$15.217.18xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$3.2733.40xyesBook value floor: BV/sh $3.27, ROE negative (excluded from median)
Two-Stage Excess ReturnAsset$2.9437.15xyesBook value with convergence: BV/sh $3.27, ROE converges to ke (excluded from median)
Discounted Future Market CapGrowth$33.993.21xyesRev $0.8B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.6x / 12.0x / 14.4x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$5.2920.64xyesMargin ramp: -50% → 12% over 7yr, rev growth 30% (input: historical growth; tapered) (excluded from median)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$15.217.18xyesRevenue $0.82B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$653.5m
Interest coverage-13.0x
Share count CAGR (dilution)16.0%
Burning cashyes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Bull Case

What the market is pricing in is a successful transformation from a single-drug rare-disease company into a multi-product respiratory franchise, and for once the fundamentals are starting to back the bet rather than just promise it. The pivotal event already happened: the FDA approved brensocatib, branded BRINSUPRI, as the first and only treatment for non-cystic-fibrosis bronchiectasis, a condition with no prior approved therapy and a large undertreated patient population. Being first and only in a disease with no alternative is the strongest commercial position a drug can have, because physicians and payors have nothing else to reach for. The early launch numbers support the enthusiasm: BRINSUPRI generated $28.1 million in its first reported quarter, a fast start for a newly launched specialty medicine.

Underneath the new launch, the existing business is already a real, growing franchise. ARIKAYCE, Insmed's treatment for a rare lung infection, generated $114.3 million in the third quarter of 2025, up 22% year over year, and management raised full-year 2025 ARIKAYCE revenue guidance to $420 to $430 million. That is a base business growing double digits, which is what separates Insmed from a pure clinical-stage biotech: it has commercial infrastructure, a salesforce calling on pulmonologists, and a revenue stream that funds part of the build-out. The international expansion is underway too, with a positive European regulatory opinion for brensocatib and an application accepted in Japan.

The pipeline extends the runway beyond the two launched products. Insmed plans to submit a supplemental application to expand ARIKAYCE to all patients with MAC lung disease in the second half of 2026, pending results from the ENCORE trial, which would meaningfully enlarge the addressable population for the existing drug. The bull case is that Insmed has crossed the hardest threshold in biotech, turning a pipeline into approved, selling products, and now has two growing franchises, a first-and-only positioning in a large indication, and label-expansion optionality on top. For a company that has executed its regulatory milestones, the question shifts from whether the drugs work to how big they get.

Bear Case

The clearest concern is how Insmed has paid for this transformation, and the answer is by issuing stock. The share count has risen about 16% a year, heavy dilution that means every existing holder owns a steadily smaller slice of whatever BRINSUPRI eventually becomes. A company that funds its growth by repeatedly selling shares is transferring value from current owners to new ones, and at a stock price that already embeds enormous success, each raise locks in that dilution at a high bar. The company is also still burning cash: operating losses are large, and while it ended 2024 with roughly $1.4 billion in cash and securities, a commercial launch and ongoing trials consume capital quickly, which is what keeps the equity issuance coming. The bear reads the 16% annual share growth as the tell that the business cannot yet self-fund and that holders will keep paying for the build-out through dilution.

The valuation leaves no room for the launch to disappoint. At about $96 (as of June 27, 2026) the stock trades near 31 times revenue, and because the company is not yet profitable, that price implies BRINSUPRI and ARIKAYCE together eventually deliver an operating margin around 33% while growing revenue at the company's ceiling for some sixteen years. Only about 14% of comparable fast-growers have sustained that kind of pace for even ten years, let alone sixteen. No valuation family reaches the price; it is rich on every standard frame, which means the market is paying for an outcome beyond what any conventional method supports. A first-and-only drug can still launch slower than hoped if payors restrict access, if the diagnosed patient pool is smaller than modeled, or if real-world uptake lags the trial enthusiasm, and any of those would leave the revenue far short of what a 31-times-sales multiple requires.

The risk profile is the standard one for a company at this stage, with sharper edges. The thesis is concentrated in two products in respiratory disease, so a safety signal, a competitive entrant, or a reimbursement setback for either drug would hit a large share of the value at once. The ENCORE trial that underpins the ARIKAYCE label expansion is itself a binary event; a disappointing readout removes a pillar of the growth story. The cash burn means the runway, while substantial, is finite, and a capital raise during a market downturn would be especially dilutive. The bear case is not that Insmed's drugs fail; they are approved and selling. It is that the price has already paid for near-perfect, decade-plus execution, while the company keeps diluting holders to fund it, leaving little margin for the ordinary disappointments that launches and trials routinely deliver.

Valuation

Because Insmed is not yet earning a normal operating profit, the price is set against its sales rather than its earnings, and at about 31 times revenue that is a demanding starting point. Inverting the price says the market expects the business to eventually reach an operating margin near 33% while growing revenue at its self-funding ceiling for roughly sixteen years. That is an extraordinarily long runway to underwrite; only about 14% of comparable fast-growers have sustained such a pace for even a decade. The price is a bet on BRINSUPRI and ARIKAYCE together becoming a large, durable, high-margin franchise, not on the current financials, which still show heavy losses.

The methods we use to triangulate confirm how far the price sits past the present. With no profits and little book value to anchor to, the asset-based and earnings-power families do not produce a meaningful reading, leaving only the growth and relative-multiple lenses, and both land far below the price. When even the forward-growth methods cannot reach it, the price is a bet beyond what any standard frame supports, which for a loss-making biotech is the market capitalizing a future commercial success as if it were already largely achieved. The peer cohort, other clinical and commercial-stage biotechs, is the right adjacency, but the comparison is directional: each of these names is its own binary story, so the cohort frames the risk category rather than pinning a value.

Solvency is the live constraint for a cash-burning company, and here it carries a caveat the methods make explicit: with operating profit deeply negative and no demonstrated through-cycle margin, a normal years-to-repay leverage figure cannot be computed honestly. Insmed ended 2024 with roughly $1.4 billion of cash and securities, which funds the launch and the trials, but the business consumes cash and the share count has been climbing about 16% a year as the company issues equity to extend the runway. What bounds the downside is the cash on hand and the value of two approved, growing drugs, not a profit stream; the dilution means even a good clinical outcome accrues to a larger share base. The buyer at this price is underwriting a long, successful commercial expansion funded partly by continued dilution, with the approved products and the cash as the floor and the sixteen-year growth assumption as the risk.

Catalysts

The defining catalyst already landed: the FDA approved brensocatib, branded BRINSUPRI, as the first and only treatment for non-cystic-fibrosis bronchiectasis, following a Priority Review with an August 12, 2025 target action date, and the company secured a positive European regulatory opinion and an accepted application in Japan. The launch is underway, with BRINSUPRI generating $28.1 million in its first reported quarter.

The base business and the pipeline supply the next catalysts. ARIKAYCE grew 22% year over year to $114.3 million in the third quarter of 2025, and management raised full-year 2025 ARIKAYCE guidance to $420 to $430 million. Looking ahead, Insmed plans to submit a supplemental application to expand ARIKAYCE to all patients with MAC lung disease in the second half of 2026, contingent on the ENCORE trial results. The events to watch are the quarter-by-quarter BRINSUPRI revenue ramp, which tests whether a first-and-only drug converts its addressable population, the ENCORE readout as a binary trial event, and the international launches, because together they determine how quickly the two-product franchise scales toward the size the price already assumes.

Peer Cohorts (Per Segment, With Filing Citations)

Biopharmaceuticals (single segment) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Insmed Q3 2025 results, 8-K · Insmed 2025 regulatory update, 8-K · Insmed 2025 results, 8-K · Insmed 2025 regulatory update · Insmed 2026 plans · Insmed 2024 results

View the full interactive INSM report on boothcheck